Effectiveness and safety of weekly semaglutide 2.4 mg for weight loss in Chinese adults with overweight or obesity

Semaglutide 2.4 mg reduces body weight and offers cardiometabolic benefits for individuals with a BMI of at least 27 kg/m².

• The trial evaluates semaglutide 2.4 mg for efficacy, tolerability, and safety among adults with overweight or obesity.
• Participants included individuals from mainland China and Taiwan.
• Eligibility was based on locally defined BMI thresholds.
• Weight-related comorbidities were considered for some participants.

Simplified